Shanghai Junshi Biosciences Co., Ltd.

DB:8SJ Stock Report

Market Cap: €4.1b

Shanghai Junshi Biosciences Valuation

Is 8SJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 8SJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 8SJ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 8SJ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8SJ?

Key metric: As 8SJ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 8SJ. This is calculated by dividing 8SJ's market cap by their current revenue.
What is 8SJ's PS Ratio?
PS Ratio11x
SalesCN¥2.07b
Market CapCN¥34.78b

Price to Sales Ratio vs Peers

How does 8SJ's PS Ratio compare to its peers?

The above table shows the PS ratio for 8SJ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.1x
BIO3 Biotest
1.8xn/a€1.4b
FYB Formycon
7.1x18.84%€495.3m
HPHA Heidelberg Pharma
31.4x39.66%€215.3m
1SXP SCHOTT Pharma KGaA
3.9x9.97%€3.8b
8SJ Shanghai Junshi Biosciences
11x24.44%€38.1b

Price-To-Sales vs Peers: 8SJ is good value based on its Price-To-Sales Ratio (11x) compared to the peer average (11.1x).

Price to Sales Ratio vs Industry

How does 8SJ's PS Ratio compare vs other companies in the DE Biotechs Industry?

9 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.8xn/aUS$1.63b
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.16%US$2.78m
8SJ 11.0xIndustry Avg. 8.2xNo. of Companies9PS0816243240+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 8SJ is expensive based on its Price-To-Sales Ratio (11x) compared to the European Biotechs industry average (8.4x).

Price to Sales Ratio vs Fair Ratio

What is 8SJ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8SJ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11x
Fair PS Ratio4.2x

Price-To-Sales vs Fair Ratio: 8SJ is expensive based on its Price-To-Sales Ratio (11x) compared to the estimated Fair Price-To-Sales Ratio (4.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 8SJ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.56
€1.79
-29.95%
18.40%€2.14€1.35n/a3
Jul ’26€2.14
€1.79
-16.20%
18.40%€2.14€1.35n/a3
Jun ’26€2.18
€1.84
-15.43%
18.55%€2.18€1.37n/a3
May ’26€1.79
€1.85
+3.13%
21.55%€2.22€1.30n/a3
Apr ’26€2.04
€1.85
-9.51%
21.55%€2.22€1.30n/a3
Mar ’26€1.76
€1.94
+9.95%
21.66%€2.33€1.36n/a3
Feb ’26€1.30
€1.92
+48.02%
21.60%€2.33€1.35n/a3
Jan ’26€1.39
€1.86
+33.56%
20.83%€2.24€1.33n/a3
Dec ’25€1.54
€1.86
+20.55%
20.83%€2.24€1.33n/a3
Nov ’25€1.51
€1.89
+25.04%
18.12%€2.24€1.42n/a3
Oct ’25€1.74
€1.69
-2.61%
16.78%€1.98€1.41n/a2
Sep ’25€1.35
€1.70
+26.22%
17.11%€2.00€1.41n/a2
Aug ’25€1.45
€1.70
+17.52%
17.11%€2.00€1.41n/a2
Jul ’25€1.33
€2.07
+55.83%
26.28%€2.76€1.43€2.143
Jun ’25€1.41
€2.94
+108.20%
45.45%€5.41€1.43€2.186
May ’25€1.40
€2.87
+105.03%
47.83%€5.37€1.18€1.796
Apr ’25€1.16
€3.72
+220.96%
47.45%€6.58€1.65€2.046
Mar ’25€1.43
€3.72
+160.36%
47.45%€6.58€1.65€1.766
Feb ’25€1.38
€3.86
+179.75%
41.35%€6.54€2.14€1.306
Jan ’25n/a
€4.03
0%
38.38%€6.61€2.17€1.396
Dec ’24€2.60
€4.03
+54.87%
38.38%€6.61€2.17€1.546
Nov ’24€2.50
€4.21
+68.38%
36.02%€6.76€2.17€1.517
Oct ’24€2.10
€4.27
+103.26%
33.29%€6.71€2.13€1.746
Sep ’24€2.40
€4.69
+95.32%
32.51%€6.67€2.12€1.356
Aug ’24€2.84
€4.92
+73.12%
29.12%€6.66€2.22€1.456
Jul ’24€2.68
€4.95
+84.72%
28.71%€6.50€2.28€1.336
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
€1.69
Fair Value
51.4% overvalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/08 15:17
End of Day Share Price 2025/07/08 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shanghai Junshi Biosciences Co., Ltd. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Congmin YuanCitic Securities Co., Ltd.
Wangbin ZhouCitigroup Inc
null nullCredit Suisse